v3.26.1
Shareholders’ Deficit (Details) - $ / shares
6 Months Ended
Feb. 02, 2026
Jan. 29, 2026
Jun. 30, 2026
Dec. 31, 2025
Shareholders’ Deficit [Line Items]        
Preference shares, par value     $ 0.0001 $ 0.0001
Preference shares, shares authorized     5,000,000 5,000,000
Preference shares, shares issued    
Preference shares, shares outstanding    
Voting rights     one  
Ordinary shares subject to possible redemption shares     30,000,000  
Warrants outstanding     23,000,000  
Prior written notice of warrants     30 days  
Trading day period     20 days  
Total equity and interest     60.00%  
Market value and newly issued price percentage     180.00%  
Redemption trigger price     $ 18  
Purchase shares     1  
Commencing days     30 days  
Business days     20 years  
Effective business days     60 days  
Completion days     30 days  
Percentage of conversion aggregate ordinary shares     25.00%  
Percentage of shares holding after IPO   25.00%    
Maximum [Member]        
Shareholders’ Deficit [Line Items]        
Trading day period     30 days  
Minimum [Member]        
Shareholders’ Deficit [Line Items]        
Trading day period     20 days  
Public Warrants [Member]        
Shareholders’ Deficit [Line Items]        
Warrants outstanding     15,000,000  
Private Placement Warrants [Member]        
Shareholders’ Deficit [Line Items]        
Warrants outstanding     8,000,000  
Commencing days     30 days  
Warrant [Member]        
Shareholders’ Deficit [Line Items]        
Warrants outstanding      
Price per share     $ 0.01  
Exercise price of warrants     $ 9.2  
Market value and newly issued price percentage     115.00%  
Founder Shares [Member]        
Shareholders’ Deficit [Line Items]        
Number of shares not subject to forfeiture 1,000,000      
Business Combination [Member]        
Shareholders’ Deficit [Line Items]        
Business combination price per share   $ 9.85    
Class A Ordinary Shares [Member]        
Shareholders’ Deficit [Line Items]        
Ordinary shares, par value     $ 0.0001 $ 0.0001
Ordinary shares, shares authorized     500,000,000 500,000,000
Ordinary shares, shares issued    
Ordinary shares, shares outstanding    
Voting rights     one  
Exercise price of warrants $ 11.5      
Effective business days     60 days  
Percentage of conversion aggregate ordinary shares     25.00%  
Class A Ordinary Shares [Member] | Public Warrants [Member]        
Shareholders’ Deficit [Line Items]        
Price per share     $ 11.5  
Class A Ordinary Shares [Member] | Warrant [Member]        
Shareholders’ Deficit [Line Items]        
Price per share     18  
Class A Ordinary Shares [Member] | Business Combination [Member]        
Shareholders’ Deficit [Line Items]        
Business combination price per share     9.2  
Class B Ordinary Shares [Member]        
Shareholders’ Deficit [Line Items]        
Ordinary shares, par value [1],[2]     $ 0.0001 $ 0.0001
Ordinary shares, shares authorized [1],[2]     50,000,000 50,000,000
Ordinary shares, shares issued [1],[2]     10,000,000 10,000,000
Ordinary shares, shares outstanding [1],[2]     10,000,000 10,000,000
Voting rights     one  
Shares subject to forfeited (in Shares)   1,000,000    
Number of additional shares issued   1,666,667    
Founder shares capitalization   10,000,000    
Class B Ordinary Shares [Member] | Founder Shares [Member]        
Shareholders’ Deficit [Line Items]        
Ordinary shares, shares outstanding   10,000,000    
[1] On February 2, 2026, the underwriters exercised their over-allotment option in full as part of the closing of the Initial Public Offering. As such, the 1,000,000 Founder Shares are no longer subject to forfeiture (Note 6).
[2] On January 29, 2026, the Company issued an additional 1,666,667 Class B ordinary shares to the Sponsor in a share capitalization, resulting in a total of 10,000,000 Founder Shares issued and outstanding, including up to 1,000,000 shares subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters. All share and per share amounts have been retroactively restated (Note 6).